Session » Vasculitis II
-
Abstract Number: 1657
Enothelin-1 Plays a Role In The Pathogenesis Of Reversible Cerebral Vasoconstriction Syndrome
-
Abstract Number: 1658
Vessel Wall Characteristics Using High Resolution Magnetic Resonance Imaging In Reversible Cerebral Vasoconstriction Syndrome and Central Nervous System vasculitis
-
Abstract Number: 1659
Systematic Review Of Amyloid Beta-Related Angiitis: A Treatable Cause Of Vasculitis Affecting Central Nervous System
-
Abstract Number: 1660
Primary Central Nervous System Vasculitis: Treatment and Course
-
Abstract Number: 1661
The Spectrum of childhood Inflammatory Brain Diseases; An Increasingly Recognised Field
-
Abstract Number: 1662
Developing Guideline For Polymyalgia Rheumatica: Prioritisation Of Outcome Measures – Perspective Of Patients, General Practitioners and Rheumatologists
-
Abstract Number: 1663
Obese Polymyalgia Rheumatica Patients Experience More Pain and Disability and Need Higher Doses Of Glucocorticoids
-
Abstract Number: 1664
Lower Tissue Expression Of IL 6 In Patients With Giant Cell Arteritis Presenting With a Cranial Ischaemic Compication
-
Abstract Number: 1665
B Cells Revisited In Giant Cell Arteritis
-
Abstract Number: 1666
Negative Temporal Artery Biopsies: Pathologic Findings Of Patients With Biopsy-Negative Giant Cell Arteritis Compared To Those Of Patients Without Arteritis
-
Abstract Number: 1667
Serum S100A8/S100A9 and S100A12 As a Marker Of Disease Activity In Giant Cell Arteritis
-
Abstract Number: 1668
Does Fibrinogen Have a Role In The Assessment Of Patients With Giant Cell Arteritis?
-
Abstract Number: 1669
The Birmingham Vasculitis Activity Score As a Measure Of Disease Activity In Patients With Giant Cell Arteritis
-
Abstract Number: 1670
Large Vessel Vasculitis: Estimating Disease Activity In Patients With Inflammatory Thoracic Aortic Aneurysms
-
Abstract Number: 1671
Cardiovascular Risk At Incidence Of Giant Cell Arteritis: A Population Based Retrospective Cohort Study
-
Abstract Number: 1672
Serious Cardiovascular Events Risk Factors In Giant Cell Arteritis. A Population-Based Study In The French Apogee Cohort
-
Abstract Number: 1673
Risk Of Myocardial Infarction In Patients With Giant Cell Arteritis: A Population-Based Study
-
Abstract Number: 1674
Acute Coronary Syndromes In Patients With Giant Cell Arteritis: A Population Based Retrospective Cohort Study
-
Abstract Number: 1675
Infections Requiring Or Acquired During Hospitalizations In Patients With Giant Cell Arteritis – a Population Based Retrospective Cohort Study
-
Abstract Number: 1676
Statins Do Not Influence Occurrence Or Prednisone Requirement Of Giant Cell Arteritis. A French Population-Based Cohort Study
-
Abstract Number: 1677
May Giant Cell Arteritis Be Characterized By Different Clinical Entity and Long-Term Outcome?
-
Abstract Number: 1678
How Similar Are Extracranial Giant Cell Arteritis and Takayasu Arteritis?
-
Abstract Number: 1679
Clinical Implications Of Antiphospholipid Antibodies In Takayasu’s Arteritis
-
Abstract Number: 1680
Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers?
-
Abstract Number: 1681
Assessment of Patients With Takayasu’s Arteritis in Routine Clinical Follow-Up With Indian Takayasu Clinical Activity Score 2010(ITAS2010)
-
Abstract Number: 1682
Patients With TAKAYASU’S Arteritis Having Persistent ACUTE PHASE Response Usually Have An Increased MAJOR Vessel Uptake By 18F-FDG-PET/CT
-
Abstract Number: 1683
High Prevalence Of Metabolic Syndrome In Takayasu Arteritis: An Increased Cardiovascular Risk and Lower Adiponectin Serum Levels
-
Abstract Number: 1684
Early Combination Immunosuppression and Serial Non-Invasive Imaging Improves Outcome In Takayasu Arteritis
-
Abstract Number: 1685
Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
-
Abstract Number: 1686
Tocilizumab In Refractory Takayasu Arteritis: a Case Series and Updated Literature Review.²
-
Abstract Number: 1687
Tocilizumab In Refractory Aortitis: A Multicenter Study Of 13 Patients
-
Abstract Number: 1688
Does The Treatment With Anti-Coagulants and Anti-Platelets Protect Giant Cell Arteritis Patients From Visual Manifestations?
-
Abstract Number: 1689
Antiplatelet Agents Decrease Ischemic Complications In Systemic Large Vessel Vasculitides: A Meta-Analysis
-
Abstract Number: 1750
Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients
-
Abstract Number: 1751
Ethnicity-Related Differences In Behçet’s Disease In a French Multiethnic Country
-
Abstract Number: 1752
Behçet´s Disease Activity: An Important Factor For Immunogenicity Of Unadjuvanted Influenza A/H1N1 Vaccine
-
Abstract Number: 1753
An Outcome Survey Of 40 Patients With Budd-Chiari Syndrome Due To BEHÇET’S Syndrome Followed By A Single Center